Annual Total Liabilities
$88.44 M
+$34.96 M+65.38%
31 December 2023
Summary:
Galectin Therapeutics annual total liabilities is currently $88.44 million, with the most recent change of +$34.96 million (+65.38%) on 31 December 2023. During the last 3 years, it has risen by +$83.03 million (+1535.68%). GALT annual total liabilities is now at all-time high.GALT Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$121.45 M
+$11.65 M+10.61%
30 September 2024
Summary:
Galectin Therapeutics quarterly total liabilities is currently $121.45 million, with the most recent change of +$11.65 million (+10.61%) on 30 September 2024. Over the past year, it has increased by +$48.42 million (+66.29%). GALT quarterly total liabilities is now at all-time high.GALT Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +65.4% | +66.3% |
| 3 y3 years | +1535.7% | +321.9% |
| 5 y5 years | +4095.5% | +9403.4% |
GALT Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +1535.7% | at high | +321.9% |
| 5 y | 5 years | at high | +4095.5% | at high | +9403.4% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Galectin Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $121.45 M(+10.6%) |
| June 2024 | - | $109.80 M(+13.2%) |
| Mar 2024 | - | $96.98 M(+9.7%) |
| Dec 2023 | $88.44 M(+65.4%) | $88.44 M(+21.1%) |
| Sept 2023 | - | $73.04 M(+2.6%) |
| June 2023 | - | $71.21 M(+13.3%) |
| Mar 2023 | - | $62.87 M(+17.6%) |
| Dec 2022 | $53.48 M(+36.4%) | $53.48 M(+32.9%) |
| Sept 2022 | - | $40.25 M(-2.1%) |
| June 2022 | - | $41.11 M(+3.3%) |
| Mar 2022 | - | $39.81 M(+1.5%) |
| Dec 2021 | $39.21 M(+625.2%) | $39.21 M(+36.2%) |
| Sept 2021 | - | $28.79 M(+76.7%) |
| June 2021 | - | $16.29 M(+249.3%) |
| Mar 2021 | - | $4.66 M(-13.8%) |
| Dec 2020 | $5.41 M(+88.3%) | $5.41 M(+115.7%) |
| Sept 2020 | - | $2.51 M(-41.8%) |
| June 2020 | - | $4.31 M(+217.1%) |
| Mar 2020 | - | $1.36 M(-52.7%) |
| Dec 2019 | $2.87 M(+36.2%) | $2.87 M(+124.7%) |
| Sept 2019 | - | $1.28 M(-8.1%) |
| June 2019 | - | $1.39 M(+40.8%) |
| Mar 2019 | - | $988.00 K(-53.1%) |
| Dec 2018 | $2.11 M(-29.0%) | $2.11 M(+28.1%) |
| Sept 2018 | - | $1.65 M(+14.7%) |
| June 2018 | - | $1.44 M(-37.1%) |
| Mar 2018 | - | $2.28 M(-23.1%) |
| Dec 2017 | $2.97 M(-21.5%) | $2.97 M(-31.6%) |
| Sept 2017 | - | $4.34 M(+23.6%) |
| June 2017 | - | $3.51 M(-19.5%) |
| Mar 2017 | - | $4.36 M(+15.4%) |
| Dec 2016 | $3.78 M(+177.9%) | $3.78 M(-7.5%) |
| Sept 2016 | - | $4.09 M(+12.4%) |
| June 2016 | - | $3.64 M(+11.9%) |
| Mar 2016 | - | $3.25 M(+139.0%) |
| Dec 2015 | $1.36 M(-20.1%) | $1.36 M(-21.2%) |
| Sept 2015 | - | $1.73 M(-9.5%) |
| June 2015 | - | $1.91 M(+47.8%) |
| Mar 2015 | - | $1.29 M(-24.2%) |
| Dec 2014 | $1.70 M(-31.5%) | $1.70 M(+23.4%) |
| Sept 2014 | - | $1.38 M(-35.7%) |
| June 2014 | - | $2.15 M(+10.8%) |
| Mar 2014 | - | $1.94 M(-22.1%) |
| Dec 2013 | $2.49 M(+51.2%) | $2.49 M(+55.0%) |
| Sept 2013 | - | $1.60 M(+7.1%) |
| June 2013 | - | $1.50 M(+1.7%) |
| Mar 2013 | - | $1.47 M(-10.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $1.64 M(-25.8%) | $1.64 M(-79.8%) |
| Sept 2012 | - | $8.14 M(-3.3%) |
| June 2012 | - | $8.42 M(-3.4%) |
| Mar 2012 | - | $8.71 M(+293.4%) |
| Dec 2011 | $2.21 M(-72.3%) | $2.21 M(-69.6%) |
| Sept 2011 | - | $7.28 M(+0.5%) |
| June 2011 | - | $7.25 M(-0.3%) |
| Mar 2011 | - | $7.26 M(-9.1%) |
| Dec 2010 | $7.99 M(+63.0%) | $7.99 M(+37.5%) |
| Sept 2010 | - | $5.81 M(-2.8%) |
| June 2010 | - | $5.98 M(-1.8%) |
| Mar 2010 | - | $6.09 M(+24.1%) |
| Dec 2009 | $4.90 M(+318.0%) | $4.90 M(+0.6%) |
| Sept 2009 | - | $4.88 M(+3.7%) |
| June 2009 | - | $4.70 M(+40.6%) |
| Mar 2009 | - | $3.34 M(+184.9%) |
| Dec 2008 | $1.17 M(-75.1%) | $1.17 M(-27.4%) |
| Sept 2008 | - | $1.62 M(-40.8%) |
| June 2008 | - | $2.73 M(-61.0%) |
| Mar 2008 | - | $7.00 M(+48.8%) |
| Dec 2007 | $4.71 M(-26.3%) | $4.71 M(+37.0%) |
| Sept 2007 | - | $3.44 M(+49.0%) |
| June 2007 | - | $2.31 M(-47.9%) |
| Mar 2007 | - | $4.42 M(-30.8%) |
| Dec 2006 | $6.38 M(+362.7%) | $6.38 M(-26.2%) |
| Sept 2006 | - | $8.65 M(-29.8%) |
| June 2006 | - | $12.32 M(-22.9%) |
| Mar 2006 | - | $15.98 M(+1057.7%) |
| Dec 2005 | $1.38 M(+37.3%) | $1.38 M(+12.7%) |
| Sept 2005 | - | $1.22 M(+38.6%) |
| June 2005 | - | $883.00 K(+7.3%) |
| Mar 2005 | - | $823.00 K(-18.1%) |
| Dec 2004 | $1.00 M(+165.9%) | $1.00 M(+65.6%) |
| Sept 2004 | - | $607.00 K(-13.0%) |
| June 2004 | - | $698.00 K(-38.4%) |
| Mar 2004 | - | $1.13 M(+199.5%) |
| Dec 2003 | $378.00 K(-43.3%) | $378.00 K(-5.7%) |
| Sept 2003 | - | $400.90 K(-4.0%) |
| June 2003 | - | $417.70 K(+33.8%) |
| Mar 2003 | - | $312.20 K(-53.2%) |
| Dec 2002 | $666.80 K(+21.1%) | $666.80 K(+54.4%) |
| Sept 2002 | - | $431.90 K(-47.1%) |
| June 2002 | - | $816.10 K(+4.6%) |
| Mar 2002 | - | $780.50 K(+41.7%) |
| Dec 2001 | $550.70 K | $550.70 K(-19.6%) |
| Sept 2001 | - | $685.00 K(-57.8%) |
| June 2001 | - | $1.62 M |
FAQ
- What is Galectin Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Galectin Therapeutics?
- What is Galectin Therapeutics annual total liabilities year-on-year change?
- What is Galectin Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly total liabilities year-on-year change?
What is Galectin Therapeutics annual total liabilities?
The current annual total liabilities of GALT is $88.44 M
What is the all time high annual total liabilities for Galectin Therapeutics?
Galectin Therapeutics all-time high annual total liabilities is $88.44 M
What is Galectin Therapeutics annual total liabilities year-on-year change?
Over the past year, GALT annual total liabilities has changed by +$34.96 M (+65.38%)
What is Galectin Therapeutics quarterly total liabilities?
The current quarterly total liabilities of GALT is $121.45 M
What is the all time high quarterly total liabilities for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly total liabilities is $121.45 M
What is Galectin Therapeutics quarterly total liabilities year-on-year change?
Over the past year, GALT quarterly total liabilities has changed by +$48.42 M (+66.29%)